Scpharmaceuticals (NASDAQ:SCPH) Upgraded at ValuEngine

ValuEngine upgraded shares of Scpharmaceuticals (NASDAQ:SCPH) from a hold rating to a buy rating in a report published on Thursday morning, ValuEngine reports.

A number of other analysts also recently weighed in on the stock. HC Wainwright began coverage on shares of Scpharmaceuticals in a report on Tuesday, October 15th. They set a buy rating and a $13.00 price target for the company. Zacks Investment Research downgraded shares of Scpharmaceuticals from a buy rating to a hold rating in a report on Wednesday, October 9th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $8.00.

SCPH stock traded down $0.35 during midday trading on Thursday, hitting $4.29. The company’s stock had a trading volume of 16,800 shares, compared to its average volume of 31,736. The company has a debt-to-equity ratio of 0.34, a current ratio of 10.48 and a quick ratio of 6.04. The stock has a market capitalization of $86.46 million, a P/E ratio of -2.70 and a beta of 0.79. Scpharmaceuticals has a twelve month low of $2.44 and a twelve month high of $7.85. The company’s fifty day moving average price is $5.59 and its 200 day moving average price is $4.90.

Scpharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.12. Equities analysts expect that Scpharmaceuticals will post -1.66 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Eversept Partners LP acquired a new position in Scpharmaceuticals during the 2nd quarter worth approximately $556,000. Alambic Investment Management L.P. acquired a new position in Scpharmaceuticals during the 2nd quarter worth approximately $191,000. Jacobs Levy Equity Management Inc. increased its position in Scpharmaceuticals by 55.8% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock worth $118,000 after purchasing an additional 13,225 shares in the last quarter. Paloma Partners Management Co acquired a new position in Scpharmaceuticals during the 2nd quarter worth approximately $96,000. Finally, Matisse Capital acquired a new position in Scpharmaceuticals during the 3rd quarter worth approximately $86,000. 39.66% of the stock is owned by institutional investors.

About Scpharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

Read More: Stock Symbols Definition, Examples, Lookup

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.